Qurient Teams Up with Lonza, Faces Test in Monetizing Anticancer Drug Candidate
Predicted impact: Medium· Actual: −8.9% vs sector, volume 1.1× normal (5 trading days)
Licensing and co-commercialization deal with Lonza; size undisclosed, so impact is uncertain.